StockLens

Granules India Limited (GRANULES) share price and analysis

GRANULES last traded at ₹797.50 (-2.21%) on the NSE. Market cap ₹21,754 Cr (Small cap), Pharma & Healthcare sector.

Overall rating: 7.5/10 (Good)

Long-term view: Strong long-term candidate. Business quality and valuation clearly outweigh the weaknesses. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.

Strengths of GRANULES

Weaknesses of GRANULES

Key numbers

NumberValueAssessmentNormal range
P/E (TTM)27.9Cheaper than peers37.2–49.5 (sector median 41.3)
Forward P/E21.0Profits expected to growbelow today's P/E (27.9) and near 41
Price / book3.06Normal2–6
EPS (TTM)₹28.57Profitableabove ₹0
Return on equity13.5%Average15%+ (below 10% is weak)
Debt / equity0.17Low debtbelow 1.0 (under 0.5 is great)
Net margin12.1%Healthy10%+ (below 5% is thin)
Operating margin17.3%Average20%+ strong, below 10% thin
Revenue growth+20.3%Growing well10%+ a year (below 3% is weak)
Profit growth+30.7%Growing well10%+ a year (falling is weak)
Dividend yield0.21%Small payout1.5%+ (none is fine for growth firms)
Current ratio2.60Comfortable1.5+ (below 1 is tight)
52W high₹923.6514% below · near the highprice in the top 40% of its 52-week range
52W low₹529.85Price is 51% above it
50-DMA₹834.49Price 4.4% belowprice above it = short-term uptrend
200-DMA₹752.33Price 6.0% aboveprice above it = long-term uptrend
1Y return+45.0%Beat the Nifty 50Nifty 50 did −1.4%
Beta0.12Steadier than the market0.8–1.3 (1 = moves with market)
Promoter / insider39.6%Moderate stake50%+ shows owner commitment
Institutions23.0%Moderate interest30%+ is strong
Analyst target₹903.2513.3% upside · 8 analysts8%+ upside

Questions about GRANULES

What is the share price of Granules India Limited (GRANULES) today?

GRANULES last traded at ₹797.50 (-2.21% on the day) on the NSE. Its 52-week range is ₹529.85 to ₹923.65. Prices are delayed and come from Yahoo Finance.

Is GRANULES a good stock for the long term?

StockLens rates GRANULES 7.5 out of 10 (Good) overall. Its long-term verdict is "Strong long-term candidate": Business quality and valuation clearly outweigh the weaknesses. Strengths: cheap vs peers, uptrend, revenue growth. Concerns: cash burn, soft momentum.

Is GRANULES share overvalued?

GRANULES trades at a P/E of 27.9 against a Pharma & Healthcare median of 41.3, which StockLens rates as "Cheaper than peers". Its price-to-book ratio is 3.06.

Is GRANULES good for short-term trading?

The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 6.0% above its 200-day average and 14-day RSI is 45.

Which stocks are similar to GRANULES?

Similar Pharma & Healthcare stocks of comparable size include Natco Pharma, Biocon, Alkem Laboratories, Glenmark Pharmaceuticals, Lupin. You can compare up to 4 of them side by side on StockLens.

About Granules India Limited

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Stocks similar to GRANULES

Compare GRANULES with NATCOPHARM, BIOCON, ALKEM

Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.